ALNY Financial Facts

Net revenues from research collaborators: 8.71M
Other (expense) income: 229K
See Full Income Statement

Other long-term liabilities: 1.78M
Total current liabilities: 70.58M
See Full Balance Sheet

Alnylam Pharmaceuticals, Inc. (ALNY) Earnings

  |   Expand Research on ALNY
Next EPS Date 8/6/21 *Est. EPS Growth Rate -7.9% *Last Qtr.
Average EPS % Beat Rate +6.1% Revenue Growth Rate +78.5% *Last Qtr.
Average % Move 1-Wk after EPS -7.8% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
4/29/21 Q121 -$1.64-$1.75 +$0.11$177.6M$168.74M N/A Details
2/11/21 Q420 -$1.60-$1.76 +$0.16$163.6M$146.07M N/A Details
11/5/20 Q320 -$1.58-$1.66 +$0.08$125.9M$120.75M N/A Details
8/6/20 Q220 -$1.67-$1.74 +$0.07$104M$99.48M N/A Details
5/6/20 Q120 -$1.52-$1.89 +$0.37$99.5M$91.56M N/A Details
2/6/20 Q419 -$1.98-$2.22 +$0.24$71.68M$71.92M N/A Details
10/31/19 Q319 -$1.50-$2.04 +$0.54$70.1M$56.41M N/A Details
8/6/19 Q219 -$2.02-$1.86 -$0.16$44.7M$69.2M N/A Details